We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
+24.79%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$168M
AUM Growth
+$38.4M
Cap. Flow
+$8.96M
Cap. Flow %
5.32%
Top 10 Hldgs %
99.46%
Holding
12
New
2
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$11.7M
2
BIOA
BioAge Labs
BIOA
+$10.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$784K

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$13.8M
2
ALGS icon
Aligos Therapeutics
ALGS
+$260K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$8.95B
$73.1M 43.38%
639,539
-153,497
-19% -$13.8M
INZY
2
DELISTED
Inozyme Pharma
INZY
$23.5M 13.95%
4,494,851
– –
ARQT icon
3
Arcutis Biotherapeutics
ARQT
$3.29B
$19.7M 11.71%
2,120,508
+79,400
+4% +$784K
OCS icon
4
Oculis Holding
OCS
$721M
$19.6M 11.61%
1,595,918
– –
ZBIO
5
Zenas BioPharma
ZBIO
$2B
$11M 6.54%
+650,695
New +$11.7M
BIOA
6
BioAge Labs
BIOA
$496M
$11M 6.51%
+527,647
New +$10.6M
EXAI
7
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$3.76M 2.23%
770,500
– –
RLYB icon
8
Rallybio
RLYB
$86.7M
$2.81M 1.67%
300,581
– –
VIGL
9
DELISTED
Vigil Neuroscience
VIGL
$1.91M 1.13%
560,595
– –
BOLT icon
10
Bolt Biotherapeutics
BOLT
$6.82M
$1.23M 0.73%
94,573
– –
IOBT
11
DELISTED
IO Biotech
IOBT
$907K 0.54%
864,197
– –
ALGS icon
12
Aligos Therapeutics
ALGS
$43.4M
– –
-29,729
Closed -$260K

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q3 2024 Portfolio in Review

As of Q3 2024, Pivotal bioVenture Partners Investment Advisor held 12 positions worth $168M, up 30% from $130M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Pivotal bioVenture Partners Investment Advisor deployed $8.96M of net new capital in Q3 2024, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Zenas BioPharma: 650,695 shares worth $11M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Vaxcyte, an estimated $13.8M trimmed.

  • Pivotal bioVenture Partners Investment Advisor's largest Q3 2024 buy was Zenas BioPharma: 650,695 shares worth $11M.
  • Pivotal bioVenture Partners Investment Advisor added most to Arcutis Biotherapeutics in Q3 2024, an estimated $784K increase.
  • Pivotal bioVenture Partners Investment Advisor's biggest Q3 2024 reduction was Vaxcyte, cutting an estimated $13.8M.
  • Pivotal bioVenture Partners Investment Advisor fully exited Aligos Therapeutics in Q3 2024, selling an estimated $260K.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 99% of its $168M portfolio in Q3 2024.
  • Pivotal bioVenture Partners Investment Advisor opened 2 new positions and closed 1 in Q3 2024.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value rose 30% quarter-over-quarter to $168M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q3 2024, filed 13 Nov 2024.